October 2025: Dr. Thomas K. Karikari – African Male Researcher of the Month

Illustrative Image: October 2025: Dr. Thomas K. Karikari – African Male Researcher of the Month
Image Source & Credit: University of Pittsburgh
Ownership and Usage Policy

Profile Overview

Dr. Thomas K. Karikari is a Ghanaian-born neuroscientist, internationally acclaimed for his pioneering contributions to biofluid biomarker research in Alzheimer’s disease and related neurodegenerative disorders. He serves as Assistant Professor of Psychiatry and Director of the Biofluid Biomarker Laboratory at the University of Pittsburgh, where his work bridges the worlds of molecular neuroscience, clinical chemistry, and translational medicine.

Renowned for developing accessible, blood-based diagnostic tools for early detection and monitoring of Alzheimer’s disease, Dr. Karikari’s scientific vision focuses on transforming complex laboratory innovations into real-world, equitable healthcare solutions—particularly for resource-limited and community-based settings.

In 2025, Dr. Karikari was honored among the “Top Ten African Scholars to Watch” by The Africa Report and recognized as a 2025 Highly Cited Researcher by Clarivate, cementing his status as one of the most influential neuroscientists of his generation. He also received the Chancellor’s Distinguished Research Award from the University of Pittsburgh and previously earned the Astrup Prize in Clinical Chemistry and the Best Alzheimer Publication Award from the Swedish Alzheimer Foundation.

Research and Leadership

At the helm of the Karikari Laboratory, located at UPMC Western Psychiatric Hospitals, Dr. Karikari leads an interdisciplinary team dedicated to unraveling the biochemical and molecular mechanisms that drive neurodegenerative diseases. His laboratory employs advanced mass spectrometry and biochemical assays to identify, validate, and clinically implement biomarkers that can transform how Alzheimer’s and related diseases are diagnosed and monitored.

Among his notable scientific achievements are:

• Development of the first commercially available plasma p-tau181 assay, now a global standard in Alzheimer’s biomarker diagnostics.

• Creation of innovative immunoassay methods for plasma p-tau212, p-tau217, and p-tau231—markers now pivotal in research and therapeutic trials.

• Introduction of a plasma brain-derived tau marker, selectively quantifying tau originating from the central nervous system, providing a more accurate measure of brain pathology.

• Establishment of a streamlined immunoprecipitation–mass spectrometry method for quantifying plasma amyloid beta peptides, enhancing diagnostic precision and efficiency.

These breakthroughs have undergone rigorous validation across international research cohorts and are now extensively applied in clinical diagnostics, prognostic evaluations, and Alzheimer’s therapeutic trials.

Translational Impact and Clinical Innovation

Beyond discovery science, Dr. Karikari is deeply invested in ensuring that diagnostic technologies are accessible and scalable. He has developed preanalytical and collection protocols that simplify blood and cerebrospinal fluid (CSF) sampling—making biomarker testing feasible in community-based and low-resource environments.

His work directly supports the mission of the National Institute on Aging’s Alzheimer’s Program Project Grant, where he leads the Fluid Biomarker Core, coordinating large-scale studies that handle and analyze thousands of biospecimens.

Professional Roles and Affiliations

• Assistant Professor of Psychiatry, University of Pittsburgh

• Director, Biofluid Biomarker Laboratory

• Head, Mass Spectrometry Program and Single Molecule Array Biomarker Program

• Lead, Fluid Biomarker Core, National Institute on Aging Alzheimer’s Program Project Grant

Professional Affiliations:

• Member, International Society to Advance Alzheimer’s Research and Treatment (ISTAART)

• Member, Committee for Aid in Education in Neurochemistry, International Society for Neurochemistry

Awards and Recognitions

• 2025 Top Ten African Scholars to Watch (The Africa Report)

• 2025 Highly Cited Researcher, Clarivate Analytics

• Chancellor’s Distinguished Research Award, University of Pittsburgh

• Astrup Prize in Clinical Chemistry, Nordic Federation for Clinical Chemistry

• Best Alzheimer Publication Award, Swedish Alzheimer Foundation (multiple years)

• Best Alzheimer Publication Award, Swedish Alzheimer Foundation

• Distinguished Contributions to Neurochemistry Award, University of Gothenburg

Education and Training

• PhD in Neuroscience, University of Warwick, Life Sciences

• Advanced Training in Clinical Neurochemistry, University of Gothenburg

Scientific Vision and Philosophy

For Dr. Karikari, science is not just discovery—it’s translation. His vision is to build diagnostic bridges that connect advanced neuroscience to clinical practice in every corner of the world.

“The most interesting and rewarding aspect of our work is identifying new biomarker candidates and innovating diagnostic tools for some of the world’s most debilitating diseases. We feel most accomplished when we develop simple and accessible blood-based biomarker tools to support early disease detection and treatment,”
— Dr. Thomas K. Karikari, The Africa Report